REGULATORY

Daiichi Sankyo's Herceptin Biosimilar Now in Line for September Approval as It Clears MHLW Panel

August 6, 2018

- Only subscribers can save articles.
  
  Sign In
  
  Subscribe

Daiichi Sankyo’s Herceptin (trastuzumab) biosimilar cleared a key health ministry advisory panel on August 3, opening the way for approval both in gastric and breast cancer indications in September and NHI reimbursement listing in November, if all goes well. The…

To read the full story

Pfizer’s Lorlatinib Gets 1st Conditional OK; MHLW Approves Astellas AML Drug and More
September 25, 2018
Opdivo Defended Crown with Ono’s Asia Sales Added, but Keytruda Triumph Would Come Soon
August 6, 2018
Daiichi Sankyo’s Herceptin Biosimilar Might Hit Market as Early as November, Breast Cancer Use Also Eyed
July 23, 2018

REGULATORY

Government Unveils Four-Chapter Outline for 2026 Honebuto
June 26, 2026
LDP, Ishin Leave Chuikyo Reform to Party Negotiators after Talks Stall
June 26, 2026
Japan Targets Global-Level Growth for Domestic Patented Drug Market
June 25, 2026
Paxlovid, Awiqli Braced for NHI Price Cuts after CEAs
June 25, 2026
Drug Pricing to Be Applied to Oncolys Oncolytic Virus Therapy
June 25, 2026

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COLUMN

The Psychology of ‘Stuck’: Understanding Why Changing Jobs Feels So Hard

By Philip Carrigan

Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…

COMMENTARY

Adaptation, Diversification Key as Drug Wholesalers Face Profit Squeeze

By Tatsuya Otsuka

Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…